PALIVIZUMAB and COUGH

Overview

COUGH is the #5 most commonly reported adverse reaction for PALIVIZUMAB, manufactured by Swedish Orphan Biovitrum AB (publ). There are 1,017 FDA adverse event reports linking PALIVIZUMAB to COUGH. This represents approximately 4.1% of all 24,586 adverse event reports for this drug.

Patients taking PALIVIZUMAB who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

COUGH is moderately reported among PALIVIZUMAB users, representing a notable but not dominant share of adverse events.

Other Side Effects of PALIVIZUMAB

In addition to cough, the following adverse reactions have been reported for PALIVIZUMAB:

• RESPIRATORY SYNCYTIAL VIRUS INFECTION — 2,083 reports
• PYREXIA — 1,437 reports
• BRONCHIOLITIS — 1,267 reports
• DEATH — 1,063 reports
• PNEUMONIA — 939 reports
• DYSPNOEA — 777 reports
• VOMITING — 651 reports
• NASOPHARYNGITIS — 635 reports
• INFLUENZA — 493 reports
• BRONCHITIS — 417 reports

Other Drugs Associated with COUGH

The following drugs have also been linked to cough in FDA adverse event reports:

Does PALIVIZUMAB cause COUGH?

COUGH has been reported as an adverse event in 1,017 FDA reports for PALIVIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is COUGH with PALIVIZUMAB?

COUGH accounts for approximately 4.1% of all adverse event reports for PALIVIZUMAB, making it a notable side effect.

What should I do if I experience COUGH while taking PALIVIZUMAB?

If you experience cough while taking PALIVIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages